IT8449184A1 - Agente attivo nel trattamento di tossicomania in particolare da eroina costituito da una composizione contenente ibogaina - Google Patents

Agente attivo nel trattamento di tossicomania in particolare da eroina costituito da una composizione contenente ibogaina

Info

Publication number
IT8449184A1
IT8449184A1 IT1984A49184A IT4918484A IT8449184A1 IT 8449184 A1 IT8449184 A1 IT 8449184A1 IT 1984A49184 A IT1984A49184 A IT 1984A49184A IT 4918484 A IT4918484 A IT 4918484A IT 8449184 A1 IT8449184 A1 IT 8449184A1
Authority
IT
Italy
Prior art keywords
toxicomania
heroin
treatment
active agent
ibogaine
Prior art date
Application number
IT1984A49184A
Other languages
English (en)
Other versions
IT1178249B (it
IT8449184A0 (it
Original Assignee
Lotsop Howard S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lotsop Howard S filed Critical Lotsop Howard S
Publication of IT8449184A0 publication Critical patent/IT8449184A0/it
Publication of IT8449184A1 publication Critical patent/IT8449184A1/it
Application granted granted Critical
Publication of IT1178249B publication Critical patent/IT1178249B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
IT49184/84A 1983-11-18 1984-11-19 Agente attivo nel trattamento di tossicomania, in particolare da eroina, costituito da una composizione contenente ibogaina IT1178249B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/553,138 US4499096A (en) 1983-11-18 1983-11-18 Rapid method for interrupting the narcotic addiction syndrome

Publications (3)

Publication Number Publication Date
IT8449184A0 IT8449184A0 (it) 1984-11-19
IT8449184A1 true IT8449184A1 (it) 1986-05-19
IT1178249B IT1178249B (it) 1987-09-09

Family

ID=24208273

Family Applications (1)

Application Number Title Priority Date Filing Date
IT49184/84A IT1178249B (it) 1983-11-18 1984-11-19 Agente attivo nel trattamento di tossicomania, in particolare da eroina, costituito da una composizione contenente ibogaina

Country Status (11)

Country Link
US (1) US4499096A (it)
EP (1) EP0163697B1 (it)
AU (1) AU576538B2 (it)
CA (1) CA1237986A (it)
DE (1) DE3482305D1 (it)
DK (1) DK156376C (it)
IE (1) IE58567B1 (it)
IL (1) IL73585A (it)
IT (1) IT1178249B (it)
NO (1) NO844573L (it)
WO (1) WO1985002115A1 (it)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587243A (en) * 1985-07-15 1986-05-06 Lotsof Howard S Rapid method for interrupting the cocaine and amphetamine abuse syndrome
EP0279114B2 (en) * 1986-11-21 1995-08-23 Glaxo Group Limited Medicaments for the treatment or prevention of the withdrawal syndrome
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
US4857523A (en) * 1988-07-18 1989-08-15 Nda International, Inc. Rapid method for attenuating the alcohol dependency syndrome
US5629307A (en) * 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US5152994A (en) * 1990-05-31 1992-10-06 Lotsof Howard S Rapid method for interrupting or attenuating poly-drug dependency syndromes
MX9701430A (es) * 1994-07-25 1997-12-31 Nda Int Inc Un metodo de tratamiento de dependencia quimica en mamiferos y una composicion para el mismo.
DE69635737D1 (de) * 1995-08-08 2006-04-06 Albany Medical College Albany Ibogamin verwandte verbindungen
US5616575A (en) * 1995-12-04 1997-04-01 Regents Of The University Of Minnesota Bioactive tricyclic ibogaine analogs
ES2435722T3 (es) * 1997-09-04 2013-12-23 Demerx, Inc. Noribogaína en el tratamiento del dolor y de la adicción a drogas
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
US20030199439A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Compositions of alpha3beta4 receptor antagonists and opioid agonist analgesics
US20030199496A1 (en) * 2002-04-22 2003-10-23 Simon David Lew Pharmaceutical compositions containing alpha3beta4 nicotinic receptor antagonists and methods of their use
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7157102B1 (en) 2002-05-31 2007-01-02 Biotek, Inc. Multi-layered microcapsules and method of preparing same
US20040266659A1 (en) * 2003-06-27 2004-12-30 Stephen LaBerge Substances that enhance recall and lucidity during dreaming
US20050251442A1 (en) * 2004-05-07 2005-11-10 Joseph Ficalora Consumer incentive system and business method
US8267851B1 (en) 2009-06-16 2012-09-18 James M Kroll Method and apparatus for electrically generating signal for inducing lucid dreaming
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
CN103079571A (zh) 2010-07-23 2013-05-01 德莫科斯公司 降伊波加因碱组合物
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
CA2855994A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
US20130178618A1 (en) 2012-01-10 2013-07-11 William Allen Boulanger Novel pharmaceutical intermediates and methods for preparing the same
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
CA2896133A1 (en) 2012-12-20 2014-06-26 Demerx, Inc. Substituted noribogaine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9550789B2 (en) 2014-06-18 2017-01-24 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
WO2016126272A1 (en) * 2015-02-04 2016-08-11 Robert Rand Rapid method of reducing motor and non-motor symptoms of parkinson's disease
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CA3138100A1 (en) 2019-04-17 2020-10-22 Compass Pathfinder Limited Treatment of depression and other various disorders with psilocybin
US20230190870A1 (en) 2020-05-20 2023-06-22 The Board Of Trustees Of The University Of Illinois Method for Treating Lysosomal Storage Diseases with Histatin Peptides
WO2022178099A1 (en) * 2021-02-17 2022-08-25 The Trustees Of Columbia University In The City Of New York Oxa-ibogaine analogues for treatment of substance use disorders
JP2025528909A (ja) 2022-08-26 2025-09-02 ザ・ジョンズ・ホプキンス・ユニバーシティー サイケデリック治療剤の標的送達のためのデンドリマー組成物
US20240100061A1 (en) 2022-09-14 2024-03-28 The Board Of Trustees Of The Leland Stanford Junior University Compositions of Iboga Alkaloids and Methods of Treatment
US12116372B1 (en) 2023-12-14 2024-10-15 William Allen Boulanger Process for preparing methyl 3-bromo-2-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)propanoate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2877229A (en) * 1959-03-10 Process for the manufacture of indoles

Also Published As

Publication number Publication date
IE842932L (en) 1985-05-18
EP0163697A4 (en) 1986-04-15
EP0163697A1 (en) 1985-12-11
DK156376C (da) 1990-01-02
IL73585A0 (en) 1985-02-28
WO1985002115A1 (en) 1985-05-23
IT1178249B (it) 1987-09-09
AU3674484A (en) 1985-06-03
CA1237986A (en) 1988-06-14
IL73585A (en) 1990-04-29
US4499096A (en) 1985-02-12
DE3482305D1 (de) 1990-06-28
DK316485A (da) 1985-07-11
NO844573L (no) 1985-05-20
IE58567B1 (en) 1993-10-06
DK156376B (da) 1989-08-14
EP0163697B1 (en) 1990-05-23
AU576538B2 (en) 1988-09-01
DK316485D0 (da) 1985-07-11
IT8449184A0 (it) 1984-11-19

Similar Documents

Publication Publication Date Title
IT8449184A1 (it) Agente attivo nel trattamento di tossicomania in particolare da eroina costituito da una composizione contenente ibogaina
FI882742A7 (fi) Hoitavia aineita ja niitä sisältäviä koostumuksia.
IT1140040B (it) Derivati di nor-tropano e granatano, loro procedimento di preparazione e loro applicazione in terapia
DE3586959D1 (de) Desinfektionsverfahren sowie zusammensetzung dafuer.
IT8419374A0 (it) Agente antibroncopneumopatico.
IT1168074B (it) Derivati amminoalchil-eterociclici, loro procedimento di preparazione e loro applicazione in terapia
AR231926A1 (es) Una composicion limpiadora desodorante del cuerpo
DE3484470D1 (de) Chemisch aktive zusammensetzung ferro-ionen enthaltend.
FI863971A7 (fi) Farmaseuttinen koostumus käytettäväksi leukopenian hoidossa.
IT1136620B (it) Procedimento per la preparazione di un agente anti-micorbico,composizioni che lo contengono e loro uso nel trattamento di infezioni
DE3169387D1 (en) Disinfecting and sterilizing composition
PH14638A (en) One-part hydrophilic treatment compositions
IT1139271B (it) Agente per la riduzione del colesterolo
ES509179A0 (es) "un metodo de fabricacion de una composicion farmaceutica de liberacion retardada en forma de pastillas que contiene como agente terapeutico ibuprofen o flurbiprofen".
NO844037L (no) Tannbehandlingspreparat inneholdende fluoridioner.
IT1167986B (it) Agente analgesico
ES519865A0 (es) Una composicion extruible y reticulable.
DK103783D0 (da) Topisk middel
IT1193929B (it) Agente assorbente di ultravioletti
ATE29878T1 (de) Pharmazeutisch wirksame verbindungen und deren herstellung.
IT1226584B (it) Agente anti-iperlipemico
DK101283D0 (da) Tandplejemiddel
IT8720800A0 (it) Composto attivo nella terapia carciovascolare.
IT1174476B (it) Agente antitumorale
IT1163077B (it) Peptide e agente ormonale contenente lo stesso come ingrendiente attivo

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19951219